Importantly, treatment with Lyc.HCL reversed the migratory and invasive phenotypes induced by TRIM22 overexpression, suggesting that Lyc.HCL exerts its anti-metastatic and anti-invasive effects by targeting TRIM22 in ESCC. The gene discussed is TRIM22; the disease is esophageal squamous cell carcinoma.